| 13-Methyltetradecanoic acid induces mitochondrial-mediated apoptosis in human bladder cancer cells. | |
| | |
MedLine Citation:
|
PMID: 20843711 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: 13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid purified from soy fermentation products, is known to induce apoptosis in many types of human cancer cells. This study was designed to investigate the molecular mechanisms involved in 13-MTD-induced apoptosis in human bladder cancer cells. METHODS AND MATERIALS: MTT assay was used to investigate the potential effects of 13-MTD on the growth and viability of human bladder cancer cells. To find out whether anti-proliferation and cell death were associated with apoptosis, we used flow cytometry to quantify the extent of apoptosis and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay to measures DNA degradation of apoptotic cells. The proteins involved in the 13-MTD induced apoptosis were examined using Western blot. RESULTS: We show that 13-MTD inhibits cellular proliferation and viability in human bladder cancer cells, which has been attributed to apoptosis. 13-MTD down-regulates Bcl-2 and up-regulates Bax. This promotes mitochondrial dysfunction, leading to the release of cytochrome c from the mitochondria to the cytoplasm, as well as the proteolytic activation of caspases. Moreover, 13-MTD down-regulates AKT phosphorylation and activates phosphorylation of p38 and c-Jun N-terminal kinase (JNK). Up-regulating AKT phosphorylation and down-regulating JNK and P38 phosphorylation could attenuate the13-MTD-induced apoptosis. CONCLUSION: Taken together, these data indicate that 13-MTD induces mitochondrial-mediated apoptosis through regulation of the AKT and MAPK pathways, suggesting 13-MTD is a potential candidate for treatment of human bladder cancer. |
| | |
Authors:
|
Tianxin Lin; Xinbao Yin; Qingqing Cai; Xinlan Fan; Kewei Xu; Li Huang; Junhua Luo; Jianping Zheng; Jian Huang |
Publication Detail:
|
Type: Journal Article Date: 2010-09-16 |
Journal Detail:
|
Title: Urologic oncology Volume: 30 ISSN: 1873-2496 ISO Abbreviation: Urol. Oncol. Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9805460 Medline TA: Urol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 339-45 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Lin Bai-xin Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical features and prognosis of patients with renal cancer and a second malignancy.
Next Document: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer.